Orgenesis Past Earnings Performance
Past criteria checks 0/6
Orgenesis has been growing earnings at an average annual rate of 3.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 15.5% per year.
Key information
3.5%
Earnings growth rate
15.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 15.5% |
| Return on equity | n/a |
| Net Margin | -10,445.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%
Mar 04
Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M
Aug 16Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study
May 06Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration
Apr 30Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?
Feb 05
Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile
Jan 28Did You Miss Orgenesis' (NASDAQ:ORGS) 71% Share Price Gain?
Dec 14Orgenesis reports Q3 results
Nov 06Revenue & Expenses BreakdownBeta
How Orgenesis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -55 | 35 | 11 |
| 30 Sep 23 | 14 | -53 | 40 | 11 |
| 30 Jun 23 | 22 | -50 | 42 | 14 |
| 31 Mar 23 | 36 | -15 | 17 | 24 |
| 31 Dec 22 | 36 | -15 | 16 | 22 |
| 30 Sep 22 | 29 | -16 | 12 | 29 |
| 30 Jun 22 | 30 | -25 | 14 | 35 |
| 31 Mar 22 | 33 | -22 | 15 | 38 |
| 31 Dec 21 | 36 | -18 | 15 | 37 |
| 30 Sep 21 | 31 | -64 | 19 | 73 |
| 30 Jun 21 | 24 | -64 | 17 | 70 |
| 31 Mar 21 | 15 | -88 | 18 | 84 |
| 31 Dec 20 | 8 | -90 | 18 | 84 |
| 30 Sep 20 | 6 | -44 | 14 | 40 |
| 30 Jun 20 | 6 | -42 | 13 | 36 |
| 31 Mar 20 | 5 | -20 | 12 | 14 |
| 31 Dec 19 | 4 | -27 | 11 | 14 |
| 31 Dec 18 | 22 | -35 | 24 | 17 |
| 30 Nov 18 | 19 | -19 | 16 | 6 |
| 31 Aug 18 | 16 | -13 | 12 | 4 |
| 31 May 18 | 13 | -12 | 11 | 3 |
| 28 Feb 18 | 11 | -12 | 10 | 3 |
| 30 Nov 17 | 10 | -12 | 9 | 2 |
| 31 Aug 17 | 9 | -17 | 10 | 2 |
| 31 May 17 | 8 | -16 | 8 | 3 |
| 28 Feb 17 | 7 | -17 | 7 | 2 |
| 30 Nov 16 | 6 | -11 | 6 | 2 |
| 31 Aug 16 | 6 | -7 | 6 | 2 |
| 31 May 16 | 5 | -6 | 5 | 1 |
| 29 Feb 16 | 4 | -3 | 4 | 1 |
| 30 Nov 15 | 3 | -4 | 4 | 1 |
| 31 Aug 15 | 2 | -3 | 4 | 0 |
| 31 May 15 | 1 | -5 | 3 | 1 |
| 28 Feb 15 | 0 | -6 | 3 | 1 |
| 30 Nov 14 | 0 | -6 | 3 | 2 |
| 31 Aug 14 | 0 | -8 | 3 | 2 |
| 31 May 14 | 0 | -5 | 4 | 2 |
| 28 Feb 14 | 0 | -5 | 4 | 2 |
| 30 Nov 13 | 0 | -6 | 4 | 1 |
| 31 Aug 13 | 0 | -5 | 4 | 1 |
Quality Earnings: ORGS is currently unprofitable.
Growing Profit Margin: ORGS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORGS is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ORGS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.